$PIRS
PIERIS PHARMACEUTICALS, INC.

2015 Q2 Form 10-Q Financial Statement

#000119312515187272 Filed on May 14, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $160.2K $217.6K $1.373M
YoY Change -77.05% -84.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.970M $2.390M $820.0K
YoY Change -16.17% 191.46%
% of Gross Profit
Research & Development $1.726M $1.525M $1.223M
YoY Change 54.22% 24.69%
% of Gross Profit
Depreciation & Amortization $70.00K $78.12K $95.55K
YoY Change -22.22% -18.24%
% of Gross Profit
Operating Expenses $3.695M $3.919M $1.223M
YoY Change 230.2% 220.5%
Operating Profit -$3.534M -$3.701M -$671.2K
YoY Change 27.6% 451.44%
Interest Expense $53.00 $4.170K $109.3K
YoY Change -99.95% -96.18%
% of Operating Profit
Other Income/Expense, Net $4.484K $769.00 $583.00
YoY Change 115.47% 31.9%
Pretax Income -$3.530M -$3.705M -$779.9K
YoY Change 22.5% 375.01%
Income Tax $0.00 $0.00 -$18.00
% Of Pretax Income
Net Earnings -$3.530M -$3.705M -$779.9K
YoY Change 22.5% 375.02%
Net Earnings / Revenue -2202.89% -1702.38% -56.81%
Basic Earnings Per Share
Diluted Earnings Per Share -$119.9K -$125.7K -$26.50K
COMMON SHARES
Basic Shares Outstanding 29.43M shares 29.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.00M $13.20M
YoY Change
Cash & Equivalents $10.03M $13.17M $3.270M
Short-Term Investments
Other Short-Term Assets $1.866M $1.276M
YoY Change
Inventory
Prepaid Expenses $732.2K $507.4K
Receivables
Other Receivables
Total Short-Term Assets $12.64M $14.97M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.811M $1.786M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $1.836M $1.809M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $12.64M $14.97M
Total Long-Term Assets $1.836M $1.809M
Total Assets $14.48M $16.77M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.100M $1.500M
YoY Change
Accrued Expenses $635.6K $413.4K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $3.022M $2.251M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $307.9K $300.0K
YoY Change
Total Long-Term Liabilities $307.9K $300.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.022M $2.251M
Total Long-Term Liabilities $307.9K $300.0K
Total Liabilities $3.330M $2.547M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$73.04M -$69.51M
YoY Change
Common Stock $29.43K $29.43K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.15M $14.23M
YoY Change
Total Liabilities & Shareholders Equity $14.48M $16.77M
YoY Change

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$3.530M -$3.705M -$779.9K
YoY Change 22.5% 375.02%
Depreciation, Depletion And Amortization $70.00K $78.12K $95.55K
YoY Change -22.22% -18.24%
Cash From Operating Activities -$2.960M -$3.720M -$420.0K
YoY Change -1.0% 785.71%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K $40.65K $1.768K
YoY Change 2199.1%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$30.00K -$40.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -170.0K -1.000M 0.000
YoY Change -113.93%
NET CHANGE
Cash From Operating Activities -2.960M -3.720M -420.0K
Cash From Investing Activities -30.00K -40.00K 0.000
Cash From Financing Activities -170.0K -1.000M 0.000
Net Change In Cash -3.160M -4.760M -420.0K
YoY Change 78.53% 1033.33%
FREE CASH FLOW
Cash From Operating Activities -$2.960M -$3.720M -$420.0K
Capital Expenditures -$30.00K $40.65K $1.768K
Free Cash Flow -$2.930M -$3.761M -$421.8K
YoY Change -2.01% 791.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.00
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
29429522 shares
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3269879
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29429522 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29429522 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
598396 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.01
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
598396 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.00
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.00
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2544500 shares
CY2015Q1 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
296452
CY2015Q1 us-gaap Liabilities
Liabilities
2547349
CY2015Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
274255
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2250897
CY2015Q1 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
23541
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
29430
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1445829
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69511782
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
413395
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
14227353
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16774702
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
85155534
CY2015Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1539706
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13167036
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2414729
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1785789
CY2015Q1 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
23541
CY2015Q1 us-gaap Assets
Assets
16774702
CY2015Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
15232
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
1275714
CY2015Q1 us-gaap Assets Current
AssetsCurrent
14965372
CY2015Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
507390
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3689382
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29279522 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29279522 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.00
CY2014Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
542360 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.00
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2519500 shares
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
242755
CY2014Q4 us-gaap Loans Payable To Bank Current
LoansPayableToBankCurrent
1270605
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3543763
CY2014Q4 us-gaap Deferred Tax Liabilities Current
DeferredTaxLiabilitiesCurrent
26522
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
29280
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-843097
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65807048
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
743866
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
18006417
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
21884168
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
84627283
CY2014Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
333988
CY2014Q4 us-gaap Liabilities
Liabilities
3877751
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1260015
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18474211
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2052221
CY2014Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
26522
CY2014Q4 us-gaap Assets
Assets
21884168
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
14810
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1207072
CY2014Q4 us-gaap Assets Current
AssetsCurrent
19805425
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
109332
CY2014Q4 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
2529400
CY2014Q4 us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
3060827
CY2014Q4 pirs Warrant Exercisable Period
WarrantExercisablePeriod
P5Y
CY2014Q4 pirs Warrant Exercisable Period
WarrantExercisablePeriod
P5Y
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
664064
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-418477
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11828974 shares
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2014Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-911
CY2014Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
18
CY2014Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3627
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-779923
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-671217
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-783532
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
583
CY2014Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-3627
CY2014Q1 us-gaap Revenues
Revenues
1372879
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1768
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-779905
CY2014Q1 us-gaap Interest Paid
InterestPaid
27059
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-479677
CY2014Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
46627
CY2014Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
260096
CY2014Q1 us-gaap Interest Expense
InterestExpense
109289
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1222745
CY2014Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
50564
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-419503
CY2014Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-410902
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-18
CY2014Q1 us-gaap Depreciation
Depreciation
95549
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1768
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
2044096
CY2014Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
82230
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
742
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
821351
CY2014Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
370122
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
CY2015Q1 dei Trading Symbol
TradingSymbol
PIRS
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
46442
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y9M
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-3720571
CY2015Q1 us-gaap Revenue Recognition Milestone Method Milestone
RevenueRecognitionMilestoneMethodMilestone
Pieris Pharmaceuticals, Inc. aggregates milestones into three categories (i) research milestones, (ii) development milestones and (iii) commercial milestones.
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
25000 shares
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
174646 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0166 pure
CY2015Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Actual results and outcomes could differ materially from management&#xB4;s estimates, judgments and assumptions.</p> </div>
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29292855 shares
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.85
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001583648
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.751 pure
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
422
CY2015Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
CY2015Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-602732
CY2015Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
1000323
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3704734
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3701333
CY2015Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4307466
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
769
CY2015Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-602732
CY2015Q1 us-gaap Revenues
Revenues
217621
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40648
CY2015Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
127482
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-3704734
CY2015Q1 us-gaap Interest Paid
InterestPaid
4224
CY2015Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
408218
CY2015Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
317073
CY2015Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
217335
CY2015Q1 us-gaap Interest Expense
InterestExpense
4170
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1524631
CY2015Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-2184
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5307175
CY2015Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-208047
CY2015Q1 us-gaap Restricted Stock Expense
RestrictedStockExpense
311066
CY2015Q1 us-gaap Depreciation
Depreciation
78117
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1000323
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-40648
CY2015Q1 us-gaap Costs And Expenses
CostsAndExpenses
3918954
CY2015Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
3500000
CY2015Q1 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
4235350
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-545633
CY2015Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2394323
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
217335
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
440649
CY2015Q1 pirs Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
P5Y9M18D

Files In Submission

Name View Source Status
0001193125-15-187272-index-headers.html Edgar Link pending
0001193125-15-187272-index.html Edgar Link pending
0001193125-15-187272.txt Edgar Link pending
0001193125-15-187272-xbrl.zip Edgar Link pending
d918278d10q.htm Edgar Link pending
d918278dex311.htm Edgar Link pending
d918278dex312.htm Edgar Link pending
d918278dex321.htm Edgar Link pending
d918278dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
pirs-20150331.xml Edgar Link completed
pirs-20150331.xsd Edgar Link pending
pirs-20150331_cal.xml Edgar Link unprocessable
pirs-20150331_def.xml Edgar Link unprocessable
pirs-20150331_lab.xml Edgar Link unprocessable
pirs-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending